Privacy preferences
Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
  • Forum
  • Premium
  • Stock Markets
    • MarketsLive prices, indices, and market performance
    • Morning ReviewDaily market recap and key overnight highlights
    • Stock CalendarUpcoming earnings, listings, and corporate events
    • Dividends CalendarFuture and past dividends
  • Companies
    • CompaniesBrowse and filter the full list of listed companies
    • DiscoveryInspiration for your next investment
    • IPOsNew listings and upcoming public offerings
    • AGM InvitationsAnnual general meeting dates and shareholder info
  • Stock Research
    • ResearchExpert stock analysis and recommendations
    • ArticlesNews, insights, and market commentary
    • PortfolioInderes model portfolio
  • Learn about investing
    • Analysis SchoolLearn how to read and understand stock analysis
    • inderesTVVideo hub for stock research, analysis, and expert commentary
    • TranscriptsFull text records of earnings calls and investor meetings
    • Stock ComparisonCompare financials and performance across multiple stocks
    • Earnings SeasonCompare EPS estimates to reported results
    • Insider TransactionsTrack buying and selling activity by company insiders
    • Short SellingSee which listed companies have disclosed short interest
    • Virtual Analyst ChatAsk questions and get instant AI-powered investment insights
    • Compound Interest CalculatorSee how your savings grow with the power of compound interest.
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Q&A
  • Terms of service
  • Privacy policy
  • Disclaimer

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.

Coegin Pharma

2.00 SEK+3.91 %19/11 15:58
Less than 1K followers

COEGIN

NGM Growth Market

Biotechnology & Pharmaceuticals

Health Care

Overview
Financials & Estimates
Ownership
Dividend
Short Selling
Investor views
Compare
+3.91 %
-8.06 %
-35.23 %
-40.09 %
-55.07 %
-66.30 %
-61.40 %
-93.73 %
-93.73 %

Coegin Pharma is a Swedish innovation company that develops and commercializes science-based technologies for hair and skin. The company's patented ingredient for hair growth is now available in products sold through selected partners as well as through the company's own brand. A peptide for natural skin pigmentation is also in development with a planned launch in the near future. Coegin Pharma is headquartered in Lund.

Read more
Market cap
61.32M SEK
Turnover
118.21K SEK
Revenue
79K
EBIT %
-25,888.61 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%
EPS and dividend
Financial calendar
25/2
2027

Annual report '26

All
Press releases
ShowingAll content types

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Regulatory press release2026-11-18 15:30

Coegin Pharma AB publishes its interim report for the third quarter of 2026

Coegin Pharma
Press release2026-11-16 09:50

Coegin Pharma strengthens Danish pharmacy presence - VEXIENNE® expands to Køge and southern Zealand

Coegin Pharma
Press release2026-11-13 12:30

Coegin Pharma expands Nordic pharmacy presence - VEXIENNE® enters Danish pharmacies

Coegin Pharma

Join Inderes community

Don't miss out - create an account and get all the possible benefits

FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
Followings and notifications on followed companies
PREMIUM account
All company reports and deep analyses
Premium tools: model portfolio, screener, insider transactions
Premium columns: Guest column, expert insights
Inderes MCP - Inderes data directly into your AI tools
Create account
Press release2026-10-29 08:30

Coegin Pharma partners with Scandinavia's largest hair transplant clinic to introduce next-generation Follicopeptide® technology

Coegin Pharma
Press release2026-10-28 15:30

Coegin Pharma signs distribution agreement with MEDS - expanding Swedish pharmacy distribution

Coegin Pharma
Press release2026-10-15 14:30

Coegin Pharma reports positive NPP-4 safety results - advancing a potential breakthrough in sunless tanning

Coegin Pharma
Regulatory press release2026-09-30 16:20

Coegin Pharma Calls SEK 6 Million Under Previously Announced Capital Facility

Coegin Pharma
Press release2026-09-08 14:30

Coegin Pharma reports strong clinical results for Follicopeptide® in eyelashes - statistically significant increase in eyelash length confirmed

Coegin Pharma
Regulatory press release2026-08-19 13:30

Coegin Pharma AB publishes its interim report for the second quarter of 2026

Coegin Pharma
Press release2026-08-18 14:30

Coegin Pharma provides an update on product development and upcoming product launches

Coegin Pharma
Regulatory press release2026-07-22 14:41

Communiqué from the Extraordinary General Meeting of Coegin Pharma AB (publ)

Coegin Pharma
Regulatory press release2026-06-25 18:46

Kallelse till extra bolagsstämma i Coegin Pharma AB (publ)

Coegin Pharma
Regulatory press release2026-06-25 18:46

Notice of extraordinary general meeting in Coegin Pharma AB (publ)

Coegin Pharma
Regulatory press release2026-06-25 18:45

Coegin Pharma Announces a Directed Issue of Approx. SEK 6.3 Million and Secures Capital Facility Providing Access to SEK 16 Million

Coegin Pharma
Press release2026-06-16 09:30

Coegin Pharma receives highly encouraging user feedback from Hårklinikken

Coegin Pharma
Press release2026-06-15 09:00

Coegin Pharma enters distribution agreement with LYKO for launch of first VEXIENNE® Follicopeptide® product

Coegin Pharma
Press release2026-06-02 14:30

Coegin Pharma provides NPP-4 development update - INCI registration filed and commercialization preparations on track.

Coegin Pharma
Regulatory press release2026-05-21 11:00

Communiqué from the Annual General Meeting of Coegin Pharma AB (publ)

Coegin Pharma
Regulatory press release2026-05-21 09:45

Coegin Pharma AB publishes its interim report for the first quarter of 2026

Coegin Pharma
Press release2026-05-20 09:30

Coegin Pharma's partner Mercapharm prepares major commercial launch of Follicopeptide® in Poland

Coegin Pharma